WWW.IJRPR.COM

International Journal of Research Publication and Reviews

Journal homepage: www.ijrpr.com ISSN 2582-7421

Biochemical Parameters in Cervical Cancer

Thirumurugan Murali[1], Prof. Dr. Jaya Jain[2], Dr. Ashutosh[3]

[1]Research Scholar, Malwanchal University.
[2]Research Supervisor, Malwanchal University
[3]Co-Supervisor, Malwanchal University

Introduction

Cancer of the cervix is a significant public health issue all over the world and is the fourth most common form of cancer found in females. Only in 2018, there were approximately 570,000 newly diagnosed cases of cervical cancer, and 311,000 people lost their lives to the disease. These statistics are according to the World Health Organisation. In recent years, biochemical parameters have been studied as potential markers for the diagnosis, prognosis, and monitoring of cervical cancer. This work has been carried out in several different countries. The purpose of this article is to provide a summary of the most recent information regarding biochemical parameters in cervical cancer.

In the case of cervical cancer, biomarkers

A substance that can be measured within the body and provides information about the presence or progression of a disease is referred to as a biomarker. In addition to their role in disease diagnosis and monitoring treatment response, biomarkers also play an important role in prognosis. In the case of cervical cancer, biomarkers have been the subject of extensive research as a potential means of enhancing both the early detection of the disease and its treatment. There are a few different types of biomarkers that can be used to diagnose cervical cancer. These include molecular, genetic, and biochemical markers.

Biochemical parameters in cervical cancer

Biochemical parameters are substances found in the body that can be measured in bodily fluids such as blood or urine. Other bodily fluids may also be used for this purpose. Enzymes, hormones, proteins, and various other molecules are all included in these parameters. In the case of cervical cancer, a number of different biochemical parameters, such as tumour markers, inflammatory markers, and oxidative stress markers, have been investigated.

Tumour markers

Cancer cells secrete substances called tumour markers, which can be found in the blood or other bodily fluids and can be used to diagnose cancer. Cancer patients frequently have their treatment response monitored, as well as the progression of their disease, using tumour markers. Several tumour markers, such as squamous cell carcinoma antigen (SCCA), carcinoembryonic antigen (CEA), and cancer antigen 125 (CA125), have been investigated in cervical cancer.

The most prevalent form of cervical cancer is called squamous cell carcinoma, and the SCCA serine protease inhibitor is found in high levels in these tumours. The levels of SCCA have been shown to correlate with the size of the tumour, as well as the stage it is in and whether or not it has spread to the lymph nodes. SCCA has been shown to be an effective biomarker in a number of studies, both for detecting cervical cancer at an early stage and for predicting the patient's prognosis.

The carbohydrate-associated enzyme (CEA) is a glycoprotein that is frequently utilised as a tumour marker in a wide variety of cancers, including cervical cancer. In patients suffering from cervical cancer, having elevated levels of CEA has been linked to the disease's advanced stage and a poor prognosis. However, CEA is not only associated with cervical cancer; it can also be elevated in other types of cancer as well as in conditions that are not related to cancer.

Ovarian cancer patients frequently have their CA125 levels tested as a tumour marker. CA125 is a glycoprotein. On the other hand, patients suffering from cervical cancer have also been shown to have elevated levels of CA125. The levels of CA125 have been shown to correlate with the size of the tumour, as well as the stage it is in and whether or not it has spread to the lymph nodes. However, CA125 is not only associated with cervical cancer; it can also be elevated in other types of cancer as well as in conditions that are not related to cancer.

Inflammatory markers

When the immune system detects a threat, such as an infection or injury, it will respond by triggering inflammation. On the other hand, inflammation that lasts for a long time can play a role in the development and progression of cancer. Inflammatory markers are substances that are associated with

inflammation and can be measured in blood or other bodily fluids. They can also be found in other bodily fluids. Several inflammatory markers, such as C-reactive protein (CRP), interleukin-6 (IL-6), and tumour necrosis factor alpha (TNF-alpha), have been investigated in the context of cervical cancer.

The liver is responsible for producing the protein known as CRP in response to inflammation. Patients suffering from cervical cancer who have elevated levels of CRP have been found to have a poor prognosis and advanced stages of the disease. The C-reactive protein (CRP) has been shown in a number of studies to be an effective biomarker for determining the prognosis of cervical cancer.

The cytokine known as IL-6 plays a role in the control of inflammatory responses as well as immune reactions. Patients suffering from cervical cancer have been found to have elevated levels of the cytokine IL-6, which has been linked to an advanced disease stage and a poor prognosis. It has also been demonstrated that levels of IL-6 correlate with the size of the tumour, involvement of lymph nodes, and distant metastasis.

TNF-α is a cytokine

A variety of immune cells, such as macrophages, monocytes, and T cells, are responsible for the production of the cytokine known as TNF-. The cytokine tumour necrosis factor beta (TNF-) is involved in the regulation of immune responses and inflammation, and it is an essential component of the host's defence mechanism against infections and tumours. However, chronic activation of TNF- can damage tissue and contribute to the development and progression of cancer. This can occur even in the absence of cancerous cells.

Multiple studies have shown that a poor prognosis and an advanced stage of cervical cancer are associated with elevated levels of TNF-a in patients who have been diagnosed with the disease. The levels of TNF-a have also been shown to correlate with the size of the tumour, the involvement of lymph nodes, and the spread of the cancer to other parts of the body. TNF-a has been proposed as a possible biomarker that could be used to predict the prognosis of cervical cancer patients and monitor how well their treatments are working.

Oxidative stress markers

Oxidative stress is a condition that occurs when there is an imbalance between the production of reactive oxygen species (ROS) and the antioxidant defence mechanisms found within the body. ROS stands for reactive oxygen species. ROS can cause damage to cellular components such as DNA, proteins, and lipids, which can result in cellular dysfunction and play a role in the development and progression of cancer. Oxidative stress markers are substances that are associated with oxidative stress and can be measured in blood or other bodily fluids. These substances can be found in the body. Malondialdehyde (MDA), superoxide dismutase (SOD), and glutathione (GSH) are three of the oxidative stress markers that have been investigated in cervical cancer.

MDA is a marker of oxidative stress that is commonly used in the medical field. MDA is a byproduct of lipid peroxidation. Multiple studies have shown that a poor prognosis and an advanced stage of cervical cancer are associated with elevated levels of MDA in patients who have been diagnosed with the disease. The size of the tumour, the involvement of lymph nodes, and the presence of distant metastases have all been shown to correlate with MDA levels.

SOD is an enzyme that catalyses the conversion of superoxide radicals to hydrogen peroxide. Hydrogen peroxide is a byproduct of this conversion and can be further detoxified by other antioxidant enzymes. In patients with cervical cancer, decreased levels of superoxide dismutase (SOD) have been shown in multiple studies to be associated with an advanced stage of the disease and a poor prognosis.

The tripeptide GSH plays a role in the control of oxidative stress through its regulatory role. When compared to healthy controls, GSH levels have been shown to be lower in patients who have been diagnosed with cervical cancer. In patients who have cervical cancer, decreased levels of GSH have been shown in a number of studies to be associated with an advanced stage of the disease as well as a poor prognosis.

Conclusion

Cervical cancer is a significant public health issue that affects people all over the world. Detection and treatment of the disease at an early stage are essential for improving patient outcomes. Biomarkers, which also include biochemical parameters, have been the subject of extensive research as a potential method for enhancing the early detection of cervical cancer as well as its prognosis and monitoring. In the case of cervical cancer, a number of different biochemical parameters, such as tumour markers, inflammatory markers, and oxidative stress markers, have been investigated. These parameters have been shown to be useful in a number of studies for predicting the prognosis of cervical cancer patients as well as monitoring how well they are responding to treatment. However, additional research is required to validate these biomarkers and to create assays that are both reliable and sensitive for measuring them.

Reference

1) Alison MR, Hunt T, Forbes SJ. Minichromosome maintenance (MCM) proteins may be pre-cancer markers. Gut. 2002;50:290–1.

2) Al-Nafussi AI, Klys HS, Rebello G, et al. The assessment of proliferating cell nuclear antigen (PCNA) immunostaining in the uterine cervix and cervical squamous neoplasia. Int J Gynecol Cancer. 1993;3:154–8.

3) Antinore MJ, Birrer MJ, Patel D, et al. The human papillomavirus type 16 E7 gene product interacts with and trans-activates the AP1 family of transcription factors. EMBO J. 1996;15:1950–60

4) Antonsson A, Payne E, Hengst K, et al. The Human Papillomavirus Type 16 E7 Protein Binds Human Interferon Regulatory Factor-9 via a Novel PEST Domain Required for Transformation. J Interferon Cytokine Res. 2006;26:455–61.

5) Autier P, Coibion M, De Sutter P, et al. Cytology alone versus cytology and cervicography for cervical cancer screening: a randomized study. Obstet Gynecol. 1999;93:353–8

6) Barnard P, McMillan NA. The human papillomavirus E7 oncoprotein abrogates signaling mediated by interferon-alpha. Virology. 1999;259:305–13.

7) Bemard B, Pretet JL, Charlot JF, et al. Human papillomaviruses type 16+ and 18+ cervical carcinoma cells are sensitive to staurosporine-mediated apoptosis. Biol Cell. 2003;95:17–26.

8) Bibbo M, Klump WJ, DeCecco J, et al. Procedure for immunocytochemical detection of P16INK4 antigen in thin-layer, liquid-based specimens. Acta Cytologica. 2002;46:25–9.

9) Bolli JN, Doering DL, Bosscher JR, et al. Squamous cell carcinoma antigen: clinical utility in squamous cell carcinoma of the uterine cervix. Gynecol Oncol. 1994;55:169–73

10) Brehm A, Nielsen SJ, Miska EA, et al. The E7 oncoprotein associates with Mi2 and histone deacetylase activity to promote cell growth. EMBO J. 1999;18:2449–58.

11) Brioschi PA, Bischof P, Delafosse C, et al. Squamous cell carcinoma antigen (SCC-A) values related to clinical outcome of pre-invasive and invasive cervical carcinoma. Int J Cancer. 1991;47:376–9

12) Brotzman GL, Spitzer M. Adjunctive testing: cervicography. In: Apgar BS, Brotzman GL, Spitzer M, editors. Colposcopy: Principles and practice. Philadelphia: Saunders; 2002. pp. 73–84

13) Chatterjee SK, Zetter BR. Cancer biomarkers: knowing the present and predicting the future. Future Oncol. 2005;1:37–50

14) Chen JJ, Reid CE, Band V, et al. Interaction of papillomavirus E6 oncoproteins with a putative calcium-binding protein. Science. 1995;269:529–31.

15) Chen TM, Defendi V. Functional interaction of p53 with HPV18 E6, c-myc and H-ras in 3T3 cells. Oncogene. 1992;7:1541–7.

16) Cole DJ, Brown DC, Crossley F, et al. Carcinoma of the cervix uteri: An assessment of the relationship of tumor proliferation to prognosis. Br J Cancer. 1992;65:783–5.

17) Cook JG, Park CH, Burke TW, et al. Analysis of Cdc6 function in the assembly of mammalian prereplication complexes. Proc Natl Acad Sci USA. 2002;99:1347–52.

18) Costa S, Sideri M, Syrjanen K, et al. Combined Pap smear, cervicography and HPV DNA testing in the detection of cervical intraepithelial neoplasia and cancer. Acta Cytol. 2000;44:310–8.

19) Crombach G, Würz H, Herrmann F, et al. Bedeutung des SCC-antigens in der diagnostik und verlaufskontrolle des zervixkarzinoms. Dtsch Med Wochenschr. 1989;114:700–5.

20) Davidson EJ, Morris LS, Scott IS, et al. Minichromosome maintenance (Mcm) proteins, cyclin B1 and D1, phosphohistone H3 and in situ DNA replication for functional analysis of vulval intraepithelial neoplasia. Br J Cancer. 2003;88:257–62.

21) Davies RJ, Freeman A, Morris LS, et al. Analysis of minichromosome maintenance proteins as a novel method for detection of colorectal cancer in stool. Lancet. 2002;369:1917–9.